Semaglutide vs Tirzepatide for Women: Insulin Resistance and Results

Two molecules, two mechanisms

Semaglutide is a GLP-1 receptor agonist; tirzepatide acts on two gut-hormone pathways at once, GIP and GLP-1. Both slow gastric emptying, curb appetite and improve how the body responds to insulin. The second mechanism in tirzepatide is part of why it draws particular interest from women whose weight is driven by insulin resistance — the same machinery that sits behind much of PCOS⁴. This guide compares the two with a women's-health lens; it is educational only and not medical advice.

What the trials show

In the STEP 1 obesity trial, once-weekly semaglutide produced a mean body-weight reduction of about 15% over 68 weeks¹. Tirzepatide went further in SURMOUNT-1, with mean reductions around 20% at the highest dose². The two have also been compared head-to-head in people with type 2 diabetes: in SURPASS-2, tirzepatide lowered A1C and body weight more than semaglutide³. These trials were not PCOS-specific, but they enrolled many women and are the strongest evidence available for the medicines themselves.

Why insulin resistance shapes the choice

For a woman whose weight tracks with insulin resistance — irregular cycles, stubborn central weight, a PCOS diagnosis — the metabolic effect of treatment matters as much as the number on the scale. Both drugs improve insulin sensitivity; tirzepatide's dual action and larger average weight loss are why many women and clinicians consider it, though it is not automatically the right answer for everyone. Our GLP-1 and insulin resistance guide explains that mechanism, and the PCOS guide covers the diagnosis-specific conversation.

Making the decision with a clinician

The head-to-head data favors tirzepatide on average, but averages are not individuals. Tolerance, side effects, cost, cycle effects and contraception all feed into a real choice, and a good program can switch molecules if the first is not the right fit. That flexibility — access to both drugs under genuine oversight — is exactly what our Luna Fit Score methodology rewards. Bring your history and goals to a clinician and decide together, rather than picking a molecule from a headline.